Logo image of PRAH

Pra Health (PRAH) Stock Fundamental Analysis

NASDAQ:PRAH - Nasdaq -

165.21  -2.8 (-1.67%)

After market: 166.01 +0.8 (+0.48%)

Fundamental Rating

2

Overall PRAH gets a fundamental rating of 2 out of 10. We evaluated PRAH against 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of PRAH have multiple concerns. While showing a medium growth rate, PRAH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRAH had positive earnings in the past year.

1.2 Ratios

Industry RankSector Rank
ROA 4.98%
ROE 13.71%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 10.03%
PM (TTM) 6.4%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

There is no outstanding debt for PRAH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

PRAH has an Altman-Z score of 3.56. This indicates that PRAH is financially healthy and has little risk of bankruptcy at the moment.
PRAH has a Debt/Equity ratio of 0.74. This is a neutral value indicating PRAH is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z 3.56
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 1.21 indicates that PRAH should not have too much problems paying its short term obligations.
PRAH has a Quick Ratio of 1.21. This is a normal value and indicates that PRAH is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.21
Quick Ratio 1.21

More info and screens

5

3. Growth

3.1 Past

PRAH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.36%.
The Earnings Per Share has been growing by 19.06% on average over the past years. This is quite good.
PRAH shows a small growth in Revenue. In the last year, the Revenue has grown by 6.57%.
Measured over the past years, PRAH shows a quite strong growth in Revenue. The Revenue has been growing by 14.55% on average per year.
EPS 1Y (TTM)-1.36%
EPS 3Y12.65%
EPS 5Y19.06%
EPS Q2Q%28.57%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y12.11%
Revenue growth 5Y14.55%
Sales Q2Q%19.15%

3.2 Future

The Earnings Per Share is expected to grow by 11.49% on average over the next years. This is quite good.
Based on estimates for the next years, PRAH will show a quite strong growth in Revenue. The Revenue will grow by 9.45% on average per year.
EPS Next Y29.21%
EPS Next 2Y20.83%
EPS Next 3Y16.62%
EPS Next 5Y11.49%
Revenue Next Year19.32%
Revenue Next 2Y12.91%
Revenue Next 3Y11.31%
Revenue Next 5Y9.45%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PRAH Yearly Revenue VS EstimatesPRAH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B 5B
PRAH Yearly EPS VS EstimatesPRAH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 32.65, PRAH can be considered very expensive at the moment.
When comparing the Price/Earnings ratio of PRAH to the average of the S&P500 Index (26.60), we can say PRAH is valued slightly more expensively.
The Price/Forward Earnings ratio is 23.77, which indicates a rather expensive current valuation of PRAH.
When comparing the Price/Forward Earnings ratio of PRAH to the average of the S&P500 Index (22.39), we can say PRAH is valued inline with the index average.
Industry RankSector Rank
PE 32.65
Fwd PE 23.77
PRAH Price Earnings VS Forward Price EarningsPRAH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 23.96
PRAH Per share dataPRAH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PRAH's earnings are expected to grow with 16.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.12
PEG (5Y)1.71
EPS Next 2Y20.83%
EPS Next 3Y16.62%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PRAH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Pra Health

NASDAQ:PRAH (6/30/2021, 8:12:54 PM)

After market: 166.01 +0.8 (+0.48%)

165.21

-2.8 (-1.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A N/A
Earnings (Next)03-01 2022-03-01/amc
Inst Owners0%
Inst Owner Change-99.98%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap10.70B
Analysts60
Price Target171.11 (3.57%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 32.65
Fwd PE 23.77
P/S 3.21
P/FCF N/A
P/OCF N/A
P/B 6.88
P/tB N/A
EV/EBITDA 23.96
EPS(TTM)5.06
EY3.06%
EPS(NY)6.95
Fwd EY4.21%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS51.45
BVpS24.02
TBVpSN/A
PEG (NY)1.12
PEG (5Y)1.71
Profitability
Industry RankSector Rank
ROA 4.98%
ROE 13.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 10.03%
PM (TTM) 6.4%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.21
Quick Ratio 1.21
Altman-Z 3.56
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.36%
EPS 3Y12.65%
EPS 5Y19.06%
EPS Q2Q%28.57%
EPS Next Y29.21%
EPS Next 2Y20.83%
EPS Next 3Y16.62%
EPS Next 5Y11.49%
Revenue 1Y (TTM)6.57%
Revenue growth 3Y12.11%
Revenue growth 5Y14.55%
Sales Q2Q%19.15%
Revenue Next Year19.32%
Revenue Next 2Y12.91%
Revenue Next 3Y11.31%
Revenue Next 5Y9.45%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A